A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma

Information

• Research Project
• 9742036

• ApplicationId

  9742036

• Core Project Number

  R44CA217591

• Full Project Number

  4R44CA217591-02

• Serial Number

  217591

• FOA Number

  PA-16-302

• Sub Project Id

• Project Start Date

  5/4/2017 - 7 years ago

• Project End Date

  7/31/2020 - 4 years ago

• Program Officer Name

  EVANS, GREGORY

• Budget Start Date

  8/3/2018 - 6 years ago

• Budget End Date

  7/31/2019 - 5 years ago

• Fiscal Year

  2018

• Support Year

  02

• Suffix

• Award Notice Date

  8/3/2018 - 6 years ago

Organizations

• Syntrix BIosystems, Inc.

IC Name

• Activity

  R44

• Administering IC

  CA

• Application Type

  4

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  1125311

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

  NCI:1125311\

• Funding Mechanism

  SBIR-STTR RPGs

• Study Section

  ZRG1

• Study Section Name

  Special Emphasis Panel

• Organization Name

  SYNTRIX BIOSYSTEMS, INC.

• Organization Department

• Organization DUNS

  114845659

• Organization City

  AUBURN

• Organization State

  WA

• Organization Country

  UNITED STATES

• Organization Zip Code

  980014213

• Organization District

  UNITED STATES